Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.

Blood advances - 9 May 2023

Lachowiez Curtis A, Long Nicola, Saultz Jennifer, Gandhi Arpita, Newell Laura F, Hayes-Lattin Brandon, Maziarz Richard T, Leonard Jessica, Bottomly Daniel, McWeeney Shannon, Dunlap Jennifer, Press Richard, Meyers Gabrielle, Swords Ronan, Cook Rachel J, Tyner Jeffrey W, Druker Brian J, Traer Elie

Abstract excerpt

Risk stratification in acute myeloid leukemia (AML) remains principle in survival prognostication and treatment selection. The 2022 European LeukemiaNet (ELN) recommendations were recently published, with notable updates to risk group assignment. The complexity of risk stratification and comparative outcomes between the 2022 and 2017 ELN guidelines remains unknown. This comparative analysis evaluated outcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytogenetics
Share to ELN gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Induction Chemotherapy

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 36441905
DOI: 10.1182/bloodadvances.2022009010
PMCID: PMC10172873

Genes

ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.PMID 36441905Read ↗

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Unified classification and risk-stratification in Acute Myeloid LeukemiaSemantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.Semantic proximity Read ↗

Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update.Semantic proximity Read ↗

Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.Semantic proximity Read ↗

AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG ReportSemantic proximity Read ↗

How I treat AML incorporating the updated classifications and guidelines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.